Product Description
Anti-COVID19 Fusion Protein Vaccine
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: UMCG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: COVID-19
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04681092 |
ACT | P2 |
Completed |
COVID-19 |
2022-03-10 |
2022-04-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
2020-005997-82 |
ACT-Study | P2 |
Completed |
COVID-19 |
2022-02-09 |
2025-07-06 |
Treatments |